[go: up one dir, main page]

WO2003059375A1 - Therapie complexe pour la regeneration des tissus - Google Patents

Therapie complexe pour la regeneration des tissus Download PDF

Info

Publication number
WO2003059375A1
WO2003059375A1 PCT/JP2002/000297 JP0200297W WO03059375A1 WO 2003059375 A1 WO2003059375 A1 WO 2003059375A1 JP 0200297 W JP0200297 W JP 0200297W WO 03059375 A1 WO03059375 A1 WO 03059375A1
Authority
WO
WIPO (PCT)
Prior art keywords
cytophysiologically
active substance
cells
tissue regeneration
organ
Prior art date
Application number
PCT/JP2002/000297
Other languages
English (en)
Japanese (ja)
Inventor
Yoshiki Sawa
Satoshi Taketani
Shigeru Miyagawa
Original Assignee
Cardio Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio Incorporated filed Critical Cardio Incorporated
Priority to AU2002226683A priority Critical patent/AU2002226683A1/en
Priority to PCT/JP2002/000297 priority patent/WO2003059375A1/fr
Priority to JP2003559536A priority patent/JPWO2003059375A1/ja
Publication of WO2003059375A1 publication Critical patent/WO2003059375A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Cette invention se rapporte à une composition et à un kit de régénération d'un organe biologique et de traitement d'une maladie. Cette composition contient une substance active d'un point de vue cytophysiologique et des cellules se trouvant dans un état propre à leur transplantation dans le coeur. Ledit kit se compose de ladite substance active d'un point de vue cytophysiologique, desdites cellules et d'une instruction. Un procédé de régénération d'un organe biologique et un procédé de traitement d'une maladie sont en outre décrits. Ces procédés consistent à former la substance active sur le plan cytophysiologique et à former des cellules. Ainsi, un organe biologique lésé peut être régénéré sans qu'il soit nécessaire de recourir à la transplantation d'organe ou à un système de support avec instruments médicaux. Des maladies telles que l'infarctus notamment peuvent ainsi être traitées.
PCT/JP2002/000297 2002-01-17 2002-01-17 Therapie complexe pour la regeneration des tissus WO2003059375A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002226683A AU2002226683A1 (en) 2002-01-17 2002-01-17 Complex therapy for tissue regeneration
PCT/JP2002/000297 WO2003059375A1 (fr) 2002-01-17 2002-01-17 Therapie complexe pour la regeneration des tissus
JP2003559536A JPWO2003059375A1 (ja) 2002-01-17 2002-01-17 組織再生複合療法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2002/000297 WO2003059375A1 (fr) 2002-01-17 2002-01-17 Therapie complexe pour la regeneration des tissus

Publications (1)

Publication Number Publication Date
WO2003059375A1 true WO2003059375A1 (fr) 2003-07-24

Family

ID=11738141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/000297 WO2003059375A1 (fr) 2002-01-17 2002-01-17 Therapie complexe pour la regeneration des tissus

Country Status (3)

Country Link
JP (1) JPWO2003059375A1 (fr)
AU (1) AU2002226683A1 (fr)
WO (1) WO2003059375A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085697A1 (fr) * 2005-02-14 2006-08-17 Japan Health Sciences Foundation Traitement combine pour les maladies vasculaires cerebrales utilisant une association d’adrenomeduline et de cellules souches mesenchymateuses
JP2007537752A (ja) * 2004-05-19 2007-12-27 ザ クリーブランド クリニック ファウンデーション 治療的応用法のための遺伝的に改変された細胞
JP2011529946A (ja) * 2008-08-05 2011-12-15 コアセラピクス エスエルユー 直径１０〜２０μｍのマイクロスフェアを含む非経口組成物
US8513007B2 (en) 2009-08-28 2013-08-20 The Cleveland Clinic Foundation SDF-1 delivery for treating ischemic tissue
US8679477B2 (en) 2007-12-14 2014-03-25 The Cleveland Clinic Foundation Use of SDF-1 to mitigate scar formation
US9226978B2 (en) 2002-08-22 2016-01-05 The Cleveland Clinic Foundation Method of treating ischemic disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045775A1 (fr) * 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions et methodes modulant la vascularisation
JP2001316285A (ja) * 2000-05-01 2001-11-13 Yasuhiko Tabata 細胞と細胞増殖因子とからなる組織器官の再生のための材料

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE307195T1 (de) * 1997-07-14 2005-11-15 Osiris Therapeutics Inc Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045775A1 (fr) * 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions et methodes modulant la vascularisation
JP2001316285A (ja) * 2000-05-01 2001-11-13 Yasuhiko Tabata 細胞と細胞増殖因子とからなる組織器官の再生のための材料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONALD ORLIC ET AL.: "Mobilized bone marrow cells repair the infarcted heart, improving function and survival", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 18, August 2001 (2001-08-01), pages 10344 - 10349, XP002950780 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226978B2 (en) 2002-08-22 2016-01-05 The Cleveland Clinic Foundation Method of treating ischemic disorders
JP2007537752A (ja) * 2004-05-19 2007-12-27 ザ クリーブランド クリニック ファウンデーション 治療的応用法のための遺伝的に改変された細胞
WO2006085697A1 (fr) * 2005-02-14 2006-08-17 Japan Health Sciences Foundation Traitement combine pour les maladies vasculaires cerebrales utilisant une association d’adrenomeduline et de cellules souches mesenchymateuses
US8679477B2 (en) 2007-12-14 2014-03-25 The Cleveland Clinic Foundation Use of SDF-1 to mitigate scar formation
JP2011529946A (ja) * 2008-08-05 2011-12-15 コアセラピクス エスエルユー 直径１０〜２０μｍのマイクロスフェアを含む非経口組成物
US8513007B2 (en) 2009-08-28 2013-08-20 The Cleveland Clinic Foundation SDF-1 delivery for treating ischemic tissue
US8513213B2 (en) 2009-08-28 2013-08-20 The Cleveland Clinic Foundation SDF-1 delivery for treating ischemic tissue
US8883756B2 (en) 2009-08-28 2014-11-11 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
US9844581B2 (en) 2009-08-28 2017-12-19 The Cleveland Clinic SDF-1 delivery for treating ischemic tissue

Also Published As

Publication number Publication date
AU2002226683A1 (en) 2003-07-30
JPWO2003059375A1 (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2004009767A3 (fr) Therapie cellulaire de regeneration
WO2003082074A3 (fr) Procede et systeme permettant de traiter une tumefaction tissulaire
DE69941903D1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
WO2004003164A3 (fr) Methodes destinees a la regeneration d'organes
WO2005001080A3 (fr) Cellules derivees de tissus post-partum destinees a etre utilisees pour traiter des maladies du coeur et du systeme circulatoire
EP2465921A3 (fr) Cellules souches de cýur obtenues par biopsie
WO2004104166A3 (fr) Methodes permettant de faciliter la recuperation de fonctions de cellules souches endogenes, implantees ou transplantees au moyen d'un acide hyaluronique de poids moleculaire eleve
WO2004022155A3 (fr) Methodes et appareils permettant de traiter des disques intervertebraux
WO2007070301A3 (fr) Stérilisation et décellularisation de greffe vasculaire
WO2007024441A3 (fr) Compositions cellulaires enrichies destines a la combinaison de diverses populations cellulaires a base de cellules souches et de cellules progenitrices, leurs methodes d'utilisation, et methodes de mise en banque privee
EP2465923A3 (fr) Procédé pour l'utilisation de cellules dérivées de tissu adipeux pour le traitement de troubles cardio-vasculaires
WO2005079822A3 (fr) Composition de cicatrisation
WO1994006449A3 (fr) Regeneration du foie induite par des morphogenes
WO2003085092A3 (fr) Transplantation cellulaire pour regeneration cardiaque
WO2008006544A3 (fr) Utilisation de gélatine et d'un agent réticulant pour produire une composition thérapeutique à réticulation
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
WO2004027029A3 (fr) Croissance de cellules etrangeres chez des animaux foetaux facilite par la destruction conditionnelle et selective de cellules hotes
WO2003059375A1 (fr) Therapie complexe pour la regeneration des tissus
WO2005047469A3 (fr) Proteine isogloboside 3 synthase porcine, adnc, organisation genomique, et region regulatrice
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
NO20052949D0 (no) Implantat inneholdende dyrkede bruksceller og fremgangsmate for fremstilling
WO2006022612A3 (fr) Methodes d'utilisation de cellules regeneratrices dans le traitement d'accident vasculaire cerebral et de maladies et de troubles lies
WO2003102162A3 (fr) Nouvelles cellules dendritiques tolerogeniques et utilisations therapeutiques de celles-ci
WO2003029432A3 (fr) Cellule souche mesenchymateuse humaine
JP2004533288A5 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003559536

Country of ref document: JP

122 Ep: pct application non-entry in european phase